{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:58:15Z","timestamp":1791586695952,"version":"4.3.4"},"reference-count":79,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Blood transports nutrients and oxygen to the cells while removing the waste. It also possesses a hemostasis function to prevent excessive bleeding. However, abnormal clot formation (thrombosis) within healthy blood vessels can lead to life-threatening conditions like heart attacks, strokes, and pulmonary embolism. This review explores anticoagulants, their historical aspects, current clinical applications, and future trends. Anticoagulants play a critical role in preventing and treating thrombosis by interfering with different stages of blood clotting. The journey began with heparin, a rapidly acting injectable medication discovered in 1916. The introduction of warfarin in the 1950s revolutionized anticoagulation by offering long-term oral regimens. Today, anticoagulants are crucial for managing conditions like deep vein thrombosis and pulmonary embolism, especially in an aging population with a rising prevalence of thrombotic complications. Three main types of anticoagulants are used today: vitamin K antagonists (VKAs), injectable heparins, and direct oral anticoagulants (DOACs). Despite advancements, managing anticoagulant therapy remains complex due to individual patient variability, the need for regular monitoring, and the delicate balance between preventing thrombosis and bleeding risks. Emerging trends include the development of factor XIa inhibitors, which promise more targeted thrombosis prevention with potentially lower bleeding risks. This review highlights the ongoing innovation in anticoagulant development, the need for precise management, and potential future avenues like factor XIa inhibitors. Additionally, artificial intelligence holds promise for improving patient outcomes and addressing the complexities of thrombotic disease management by personalizing therapy and reducing bleeding risks.<\/jats:p>","DOI":"10.3390\/jcm14051647","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:28:18Z","timestamp":1740716898000},"page":"1647","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Anticoagulation Management: Current Landscape and Future Trends"],"prefix":"10.3390","volume":"14","author":[{"given":"Andaleb","family":"Kholmukhamedov","sequence":"first","affiliation":[{"name":"Versiti Blood Research Institute, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Subbotin","sequence":"additional","affiliation":[{"name":"School of Dentistry, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gorin","sequence":"additional","affiliation":[{"name":"School of Public Health, San Diego State University, San Diego, CA 92115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Ilyassov","sequence":"additional","affiliation":[{"name":"Scripps Memorial Hospital, Encinitas, CA 92024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14779072.2023.2201437","article-title":"Antiplatelet Therapy for Coronary Artery Disease in 2023: Current Status and Future Prospects","volume":"21","author":"Chandiramani","year":"2023","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.31083\/j.rcm.2021.01.256","article-title":"Platelet Reactivity in Dyslipidemia: Atherothrombotic Signaling and Therapeutic Implications","volume":"22","author":"Yang","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e26668","DOI":"10.1016\/j.heliyon.2024.e26668","article-title":"Diverse Origins of Fibrinolytic Enzymes: A Comprehensive Review","volume":"10","author":"Hazare","year":"2024","journal-title":"Heliyon"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Diwan, D., Usmani, Z., Sharma, M., Nelson, J.W., Thakur, V.K., Christie, G., Molina, G., and Gupta, V.K. (2021). Thrombolytic Enzymes of Microbial Origin: A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910468"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.trsl.2020.05.003","article-title":"Fibrinolytics for the Treatment of Pulmonary Embolism","volume":"225","author":"Stewart","year":"2020","journal-title":"Transl. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1042\/bj0291273","article-title":"The Antihaemorrhagic Vitamin of the Chick","volume":"29","author":"Dam","year":"1935","journal-title":"Biochem. J."},{"key":"ref_7","first-page":"99","article-title":"On the history of vitamin K, dicoumarol and warfarin","volume":"42","author":"Norn","year":"2014","journal-title":"Dan. Medicinhist Arbog"},{"key":"ref_8","first-page":"57","article-title":"The Anticoagulant Dicumarol","volume":"51","author":"Link","year":"1948","journal-title":"Bull. Chic. Med. Soc."},{"key":"ref_9","unstructured":"Crader, M.F., Johns, T., and Arnold, J.K. (2024). Warfarin Drug Interactions. StatPearls, StatPearls Publishing."},{"key":"ref_10","first-page":"422","article-title":"Warfarin Pharmacogenomics","volume":"34","author":"Li","year":"2009","journal-title":"Pharm. Ther."},{"key":"ref_11","first-page":"22","article-title":"Heparin, the Miracle Drug: A Brief History of Its Discovery","volume":"142","author":"Ancalmo","year":"1990","journal-title":"J. La. State Med. Soc. Off. Organ La. State Med. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/sdi.12932","article-title":"Anticoagulation in Hemodialysis: A Narrative Review","volume":"34","author":"Claudel","year":"2021","journal-title":"Semin. Dial."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/23481","article-title":"Heparin Is Essential for the Storage of Specific Granule Proteases in Mast Cells","volume":"400","author":"Humphries","year":"1999","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0005-2795(77)90110-6","article-title":"Binding of Heparin to Human Antithrombin III as Studied by Measurements of Tryptophan Fluorescence","volume":"490","author":"Einarsson","year":"1977","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Magnani, G., Denegri, A., Gurgoglione, F.L., Barocelli, F., Indrigo, E., Catellani, D., Signoretta, G., Bettella, A., Tuttolomondo, D., and Solinas, E. (2023). Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review. J. Clin. Med., 12.","DOI":"10.20944\/preprints202306.1260.v1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rajsic, S., Breitkopf, R., Rugg, C., Bukumiric, Z., Reitbauer, J., and Treml, B. (2023). Thrombotic Events Develop in 1 Out of 5 Patients Receiving ECMO Support: An 11-Year Referral Centre Experience. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031082"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rajsic, S., Breitkopf, R., Treml, B., Jadzic, D., Oberleitner, C., Oezpeker, U.C., Innerhofer, N., and Bukumiric, Z. (2023). Association of APTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093224"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for Heparin-Induced Thrombocytopenia with Unfractionated and Low-Molecular-Weight Heparin Thromboprophylaxis: A Meta-Analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral Anticoagulants","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"265S","DOI":"10.1378\/chest.126.3_suppl.265S","article-title":"New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Weitz","year":"2004","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"RE-COVER Study Group Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during Primary PCI in Acute Myocardial Infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.23736\/S2724-5683.24.06546-3","article-title":"Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban\u2014IRIS","volume":"72","author":"Lavalle","year":"2024","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ahj.2014.03.002","article-title":"The Quality of Antiplatelet and Anticoagulant Medication Administration among ST-Segment Elevation Myocardial Infarction Patients Transferred for Primary Percutaneous Coronary Intervention","volume":"167","author":"Wang","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"BCSH committee Measurement of Non-Coumarin Anticoagulants and Their Effects on Tests of Haemostasis: Guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jtha.2024.04.002","article-title":"Management of Abnormal Uterine Bleeding on Anticoagulation: The Patient-Clinician Perspective","volume":"22","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/hematology.2020000138","article-title":"Management of Heavy Menstrual Bleeding on Anticoagulation","volume":"2020","year":"2020","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/jth.14549","article-title":"Sex Matters: Practice 5P\u2019s When Treating Young Women with Venous Thromboembolism","volume":"17","author":"Bistervels","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17474086.2018.1517040","article-title":"Anticoagulation at the Extremes of Body Weight: Choices and Dosing","volume":"11","author":"McCaughan","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.01260213","article-title":"Dabigatran and Kidney Disease: A Bad Combination","volume":"8","author":"Knauf","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pds.4268","article-title":"Adherence with Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation New Users and Associated Factors: A French Nationwide Cohort Study","volume":"26","author":"Maura","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1007\/s12325-023-02620-z","article-title":"Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke","volume":"40","author":"Salam","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","article-title":"Inhibition of Factor XIa as a New Approach to Anticoagulation","volume":"30","author":"Schumacher","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated Factor XI Activity Levels Are Associated with an Increased Odds Ratio for Cerebrovascular Events","volume":"126","author":"Yang","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why Factor XI Deficiency Is a Clinical Concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert. Rev. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and Clinical Development of Factor XI Inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e13784","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Fesomersen, a Novel Antisense Inhibitor of Factor XI, in Healthy Chinese, Japanese, and Caucasian Volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human Study of Milvexian, an Oral, Direct, Small Molecule Factor XIa Inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological Profile of Asundexian, a Novel, Orally Bioavailable Inhibitor of Factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BMS-962212, a Direct, Reversible, Small Molecule Factor XIa Inhibitor in Non-Japanese and Japanese Healthy Subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a Novel Oral FXIa Inhibitor: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in a First-in-Human Study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a Novel FXI Antibody with a Unique Binding Mode, Shows Durable Effects on Markers of Anticoagulation in Humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The Contact Activation Inhibitor AB023 in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chen, R., Guan, X., Hu, P., Dong, Y., Zhu, Y., Zhang, T., Zou, J., and Zhang, S. (2022). First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.821363"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A Randomized Trial of Genotype-Guided Dosing of Warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1311388","article-title":"A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon","volume":"369","author":"Verhoef","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0037-1599153","article-title":"Point-of-Care Coagulation Testing in Cardiac Surgery","volume":"43","author":"Bolliger","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bpa.2022.08.002","article-title":"Point-of-Care Coagulation Testing for Postpartum Haemorrhage","volume":"36","author":"Collins","year":"2022","journal-title":"Best. Pract. Res. Clin. Anaesthesiol."},{"key":"ref_55","first-page":"425","article-title":"Point-of-care Coagulation Testing in Neurosurgery","volume":"53","author":"Adam","year":"2018","journal-title":"Anasthesiol. Intensivmed. Notfallmed Schmerzther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cvsm.2022.08.001","article-title":"Point-of-Care Instruments","volume":"53","author":"Stern","year":"2023","journal-title":"Vet. Clin. North. Am. Small Anim. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/nat.2015.0581","article-title":"Translation and Clinical Development of Antithrombotic Aptamers","volume":"26","author":"Nimjee","year":"2016","journal-title":"Nucleic Acid. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Vaganov, A.A., Taranushenko, T.E., Luzan, N.A., Shchugoreva, I.A., Kolovskaya, O.S., Artyushenko, P.V., Zamay, T.N., and Kichkailo, A.S. (2022). Aptamers Regulating the Hemostasis System. Molecules, 27.","DOI":"10.3390\/molecules27238593"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/ATVBAHA.115.300131","article-title":"Modulation of the Coagulation Cascade Using Aptamers","volume":"35","author":"Woodruff","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MOH.0000000000000452","article-title":"Emerging Applications of Aptamers for Anticoagulation and Hemostasis","volume":"25","author":"Chabata","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1097\/JS9.0000000000001734","article-title":"Machine Learning Guided Prediction of Warfarin Blood Levels for Personalized Medicine Based on Clinical Longitudinal Data from Cardiac Surgery Patients: A Prospective Observational Study","volume":"110","author":"Xue","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.imu.2021.100688","article-title":"Using Machine Learning to Predict Anticoagulation Control in Atrial Fibrillation: A UK Clinical Practice Research Datalink Study","volume":"25","author":"Gordon","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ihj.2022.10.002","article-title":"Development and Validation of a Mobile Application Based on a Machine Learning Model to Aid in Predicting Dosage of Vitamin K Antagonists among Indian Patients Post Mechanical Heart Valve Replacement","volume":"74","author":"Amruthlal","year":"2022","journal-title":"Indian Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lee, H., Kim, H.J., Chang, H.W., Kim, D.J., Mo, J., and Kim, J.-E. (2021). Development of a System to Support Warfarin Dose Decisions Using Deep Neural Networks. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-94305-2"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/phar.1982","article-title":"Warfarin Pharmacogenomics in Diverse Populations","volume":"37","author":"Kaye","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kanuri, S.H., and Kreutz, R.P. (2019). Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J. Pers. Med., 9.","DOI":"10.3390\/jpm9010007"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/bcp.14646","article-title":"The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation","volume":"87","author":"Ji","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14622416.2024.2428587","article-title":"Artificial Intelligence, Medications, Pharmacogenomics, and Ethics","volume":"25","author":"Haga","year":"2024","journal-title":"Pharmacogenomics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e038863","DOI":"10.1136\/bmjopen-2020-038863","article-title":"Variation in the Estimated Costs of Pivotal Clinical Benefit Trials Supporting the US Approval of New Therapeutic Agents, 2015-2017: A Cross-Sectional Study","volume":"10","author":"Moore","year":"2020","journal-title":"BMJ Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/14779072.2015.987126","article-title":"Monitoring and Reversal Strategies for New Oral Anticoagulants","volume":"13","author":"Peetermans","year":"2015","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","article-title":"Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation","volume":"16","author":"Coyle","year":"2013","journal-title":"Value Health"},{"key":"ref_72","first-page":"j5058","article-title":"Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis","volume":"359","author":"Sterne","year":"2017","journal-title":"BMJ"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M22-1258","article-title":"Anticoagulant therapy for cancer-associated thrombosis: A cost-effectiveness analysis","volume":"176","author":"Gulati","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMp1709851","article-title":"The HITECH Era in Retrospect","volume":"377","author":"Halamka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/bmjqs-2013-001874","article-title":"Electronic Health Record-Based Triggers to Detect Potential Delays in Cancer Diagnosis","volume":"23","author":"Murphy","year":"2014","journal-title":"BMJ Qual. Saf."},{"key":"ref_76","unstructured":"(2024, June 18). Health Insurance Portability and Accountability Act of 1996, Available online: https:\/\/aspe.hhs.gov\/reports\/health-insurance-portability-accountability-act-1996."},{"key":"ref_77","unstructured":"(2024, June 18). L_2016119EN.01000101.Xml. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX%3A32016R0679."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"160018","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for Scientific Data Management and Stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci. Data"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/amiajnl-2012-001023","article-title":"Patients Want Granular Privacy Control over Health Information in Electronic Medical Records","volume":"20","author":"Caine","year":"2013","journal-title":"J. Am. Med. Inform. Assoc."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:28Z","timestamp":1760028268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051647"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051647","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}